Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 3-hydroxy-3-methylglutaryl-CoA reductase pseudogene (ENSG00000275012) is a genetically inactive copy of the functional HMG-CoA reductase gene, lacking protein-coding capability due to mutations, frameshift errors, or missing regulatory elements. HMG-CoA reductase, the active enzyme, is a key regulator of cholesterol and isoprenoid biosynthesis targeted by statins, but pseudogenes such as ENSG00000275012 do not encode functional protein and are not implicated in therapeutic interventions or biological roles[3][4]. Their presence may reflect evolutionary history or genetic redundancy; however, they are not considered drug targets, have no known pathophysiological function, and are not associated with disease or clinical applications. *This distinguishes the pseudogene from functional HMG-CoA reductase, an established drug target responsible for cholesterol biosynthesis and the target of statin drugs[3][4].*
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3-hydroxy-3-methylglutaryl-CoA reductase pseudogene.